Propeller Health announced that the Food and Drug Administration (FDA) has granted clearance for its Propeller platform for use with GlaxoSmithKline‘s Ellipta inhaler, the Company’s patented dry powder inhaler.

The sensor for the Ellipta inhaler was designed and cleared as part of an agreement and research & development collaboration between Propeller and GSK. Propeller’s platform includes its proprietary sensor technology, software, and other services. Its digitally-guided therapy platform combines data from multiple sources, including linked medications, then uses machine intelligence to help patients manage their condition.  

Related Articles

The head of respiratory research & development at GSK, Dave Allen, added, “The approval of the Propeller platform for use with the Ellipta inhaler will help us understand how patients interact with the Ellipta inhaler accurately and in real-time. By exploring the benefits of sensor technology in this way, we hope to gain valuable insights into usage patterns with the ultimate goal of driving improvements in patient care while reducing the complexity and cost of clinical trials.” 

The Ellipta inhalers in GSK’s portfolio currently include: Breo Ellipta (fluticasone furoate, vilanterol), Arnuity Ellipta (fluticasone furoate), Anoro Ellipta (umeclidinium, vilanterol), and Incruse Ellipta (umeclidinium). These medications are indicated for use as maintenance treatment for airflow obstruction in chronic obstructive pulmonary disease (COPD) and/or maintenance treatment of asthma as prophylactic therapy.

For more information call (877) 251-5451 or visit